EMEA Widening of acceptance limit [Regulatives / Guidelines]

posted by Dr_Dan  – Germany, 2012-05-02 11:28 (5164 d 05:17 ago) – Posting: # 8487
Views: 4,151

Dear hiren379
IMHO you just have to point out in the protocol that the drug has no narrow therapeutic window and that a slightly higher variability of Cmax will not raise any safety concerns. This should be sufficient to allow the ethics committee to assess the study design and the planned evaluation of the results in order to give their approval.
Kind regards
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
148 visitors (0 registered, 148 guests [including 16 identified bots]).
Forum time: 16:45 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5